International Journal of Drug Delivery Technology
Volume 15, Issue 2

Retrospective Analysis of Guillain-Barré Syndrome: A Pharmaceutical Perspective 

Snehal Gojare*, Sumit Deore 

School of Pharmaceutical Sciences, Sandip University, Nashik, Maharashtra, India

Received: 17th Jan, 2025; Revised: 29th Mar, 2025; Accepted: 18th May, 2025; Available Online: 25th Jun, 2025 

ABSTRACT

One of the most common causes of flaccid paralysis, Guillain Barre Syndrome (GBS) has long been a major health problem around the world. Substantial evidence supports the autoimmune nature of this syndrome, with the autoantibody profile playing a crucial role in confirming the clinical and electrophysiological associations between GBS and various other peripheral nerve disorders. This research is aimed to assess the clinical features, electrophysiological, treatment pattern and functional outcome of a multi-centre cohort of GBS patients. Tertiary care hospitals in the Maharashtra region of India were the focus of the present retrospective observational cohort study. Data for the GBS cases admitted during June 2018 to Dec 2023 were included for the current study. Data collected were included clinical features, reported electrophysiological data, treatment and outcome. All the data were assessed with the help of statistical models. The study comprised a total of 25 participants diagnosed with GBS.  Males made up the vast majority of the GBS patients (72%). An average age at presentation was 44 ±13 years. The symptom that present most frequently was ascending or upward paralysis that happened in 20 patients (80%). The remaining common symptoms were sensory disturbances (40%), bladder and bowel complaints (28%) and difficulty in up-squatting. In this cohort analysis, COVID-19 infection was the most common antecedent event (44%). All the patients administered GBS-specific therapy of whom 84 % patients had given Intravenous Immunoglobulin (IVIG) along with Antibiotics, 12% of patients had given Plasmapheresis treatment along with IVIG and 4% of patients had given IVIG, Antibiotics, Plasmapheresis and ventilator. According to this research the maximum number of patients had a favourable functional outcome, i.e. 92% and 8% patients showed poor functional outcome.

Keywords: Guillain-Barresyndrome, Disability, Intravenous Immunoglobulin

How to cite this article: Snehal Gojare, Sumit Deore. Retrospective Analysis of Guillain-Barré Syndrome: A Pharmaceutical Perspective. International Journal of Drug Delivery Technology. 2025;15(2):503-09. doi: 10.25258/ijddt.15.2.18

REFERENCES

  1. Iqbal R, Asad MJ, Shah MB, Mahmood RT, Siddiqi S. Clinical and biochemical profile of GuillainBarré Syndrome in Pakistan. Neurosciences Journal. 2021 Jul 1;26(3):242-7.
  2. Jasti AK, Selmi C, Sarmiento-Monroy JC, Vega DA, Anaya JM, Gershwin ME. Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment. Expert review of clinical immunology. 2016 Nov 1;12(11):1175-89.
  3. Chandrasekararan P. A Study on GuillainBarre Syndrome-Clinical Profile and Treatment Outcome. International Archives of Integrated Medicine. 2020 Sep 1;7(9).
  4. Uncini A, González‐Bravo DC, Acosta‐Ampudia YY, Ojeda EC, Rodríguez Y, Monsalve DM, Ramírez‐Santana C, Vega DA, Paipilla D, Torres L, Molano‐González N. Clinical and nerve conduction features in Guillain− Barré syndrome associated with Zika virus infection in Cúcuta, Colombia. European Journal of Neurology. 2018 Apr;25(4):644-50.
  5. Langmuir AD, Bregman DJ, Kurland LT, Nathanson N, Victor M. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. American Journal of Epidemiology. 1984 Jun 1;119(6):841-79.
  6. Kajumba MM, Kolls BJ, Koltai DC, Kaddumukasa M, Kaddumukasa M, Laskowitz DT. COVID-19-associated Guillain-Barre syndrome: atypical para-infectious profile, symptom overlap, and increased risk of severe neurological complications. SN comprehensive clinical medicine. 2020 Dec;2:2702-14.
  7. Brannagan III TH. Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology. 2002 Dec 24;59(12_suppl_6):S33-40.
  8. Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain‐Barré syndrome. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2002 Jun;51(6):673-80.
  9. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. Journal of Infectious Diseases. 1997 Dec 1;176(Supplement_2):S92-8.
  10. Shangab M, Al Kaylani M. Clinical course and predictors of poor functional outcome in Guillain-Barré syndrome. A retrospective study. Dubai Medical Journal. 2020 Sep 8;3(3):93-8.
  11. Kalita J, Ranjan A, Misra UK. Outcome of Guillain–Barre syndrome patients with respiratory paralysis. QJM: An International Journal of Medicine. 2016 May 1;109(5):319-23.
  12. Hughes RA, Cornblath DR. Guillain-barre syndrome. The Lancet. 2005 Nov 5;366(9497):1653-66.
  13. Boostani R, Ramezanzadeh F, Saeidi M, Khodabandeh M. A follow-up study on Guillain-Barre syndrome and validation of Brighton criteria. Iranian Journal of Neurology. 2019 Apr 4;18(2):64.
  14. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011 Mar 21;36(2):123-33.
  15. Doets AY, Verboon C, Van Den Berg B, Harbo T, Cornblath DR, Willison HJ, Islam Z, Attarian S, Barroso FA, Bateman K, Benedetti L. Regional variation of Guillain-Barré syndrome. Brain. 2018 Oct 1;141(10):2866-77.
  16. Mateen FJ, Cornblath DR, Jafari H, Shinohara RT, Khandit D, Ahuja B, Bahl S, Sutter RW. Guillain–Barré Syndrome in India: Population-based validation of the Brighton criteria. Vaccine. 2011 Dec 6;29(52):9697-701.
  17. Li X, Xiao J, Ding Y, Xu J, Li C, He Y, Zhai H, Xie B, Hao J. Clinical and electrophysiological features of post-traumatic Guillain-Barré syndrome. BMC neurology. 2017 Dec;17:1-7.
  18. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain–Barré syndrome: incidence and mortality rates in US hospitals. Neurology. 2008 Apr 29;70(18):1608-13.
  19. Bhagat SK, Sidhant S, Bhatta M, Ghimire A, Shah B. Clinical profile, functional outcome, and mortality of Guillain-Barre syndrome: a five-year tertiary care experience from Nepal. Neurology Research International. 2019 Jun 2;2019.
  20. Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. Journal of Neurology, Neurosurgery & Psychiatry. 1998 Jan 1;64(1):74-7.
  21. Fitero A, Bungau SG, Tit DM, Endres L, Khan SA, Bungau AF, Romanul I, Vesa CM, Radu AF, Tarce AG, Bogdan MA. Comorbidities, associated diseases, and risk assessment in COVID-19—A systematic review. International Journal of Clinical Practice. 2022 Oct 31;2022.
  22. Nagarajan V, Al-Shubaili A. Clinical and neurophysiological pattern of Guillain-Barré syndrome in Kuwait. Medical Principles and Practice. 2006 Feb 16;15(2):120-5.
  23. Tian J, Cao C. Electrophysiological subtypes and prognostic factors of Guillain-Barre syndrome in northern China. Frontiers in neurology. 2019 Jul 2;10:455899.